Literature DB >> 24556303

Predictors of hemorrhagic complications from endovascular treatment of cerebral arteriovenous malformations.

José A Jordan1, Juan Carlos Llibre2, Frank Vázquez3, Raúl Rodríguez4, José A Prince5, José Carlos Ugarte2.   

Abstract

Post-embolization hemorrhage is the most severe, dramatic and morbidity-mortality-related complication in the treatment of endovascular arteriovenous malformations (AVMs). The objective of this study was to determine predictive factors of post-embolization hemorrhage. This is a retrospective study in 71 patients with cerebral AVMs having undergone 147 embolization sessions with n-butyl cyanoacrylate (n-BCA), carried out between 2006 and 2011. Clinical-demographic, morphological and treatment data as well as results were recorded. The relationship of post-procedure hemorrhage with demographic and morphological factors, percentage devascularization per session, venous drainage and whether or not post-procedure hypotension had been induced was investigated. Six post-embolization hemorrhages occurred, all in sessions characterized by extensive devascularization without the induction of post-procedure hypotension; which disappeared after a limit to the extent of devascularization per session and post-procedure hypotension were introduced. In the multivariate analysis, hemorrhage predictors were: nidus diameter < 3 cm (OR= 45.02; CI=95%:1.17-203.79; P=0.005); devascularization > 40% (OR=32.4; CI=95%: 3.142- 518.6; P=0.009) per session; intranidal aneurysms (OR=7.5; CI=95%:1.19-341.3; P=0.041) and lack of post-procedure hypotension (OR=16.51; CI=95%:1.81-324.4; P=0.049) and the association of sessions with devascularization exceeding 40% with lack of post-procedure hypotension, showed an increase in the risk of hemorrhage (OR=36.4; CI=95%:3.67-362.4; P=0.002). Extensive devascularization and the absence of post-procedure hypotension increase the risk of hemorrhage. We suggest partial, 25-30%, devascularization per session and the induction of post-procedure hypotension, which produces a 20% decrease of the basal mean arterial pressure (MAP).

Entities:  

Keywords:  arteriovenous malformations; hemorrhage, embolization; n-butyl cyanoacrylate; post-embolization hypotension; predictive factors

Mesh:

Substances:

Year:  2014        PMID: 24556303      PMCID: PMC3971145          DOI: 10.15274/INR-2014-10011

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  32 in total

Review 1.  Therapeutic embolization of arteriovenous malformations: the case for and against.

Authors:  N A Martin; R Khanna; C Doberstein; J Bentson
Journal:  Clin Neurosurg       Date:  2000

2.  Endovascular treatment of intracerebral arteriovenous malformations: experience in 49 cases.

Authors:  D Fournier; K G TerBrugge; R Willinsky; P Lasjaunias; W Montanera
Journal:  J Neurosurg       Date:  1991-08       Impact factor: 5.115

3.  Combined endovascular embolization and surgery in the management of cerebral arteriovenous malformations: experience with 101 cases.

Authors:  F Viñuela; J E Dion; G Duckwiler; N A Martin; P Lylyk; A Fox; D Pelz; C G Drake; J J Girvin; G Debrun
Journal:  J Neurosurg       Date:  1991-12       Impact factor: 5.115

4.  Blood pressure changes in feeders to cerebral arteriovenous malformations during therapeutic embolization.

Authors:  C A Jungreis; J A Horton; S T Hecht
Journal:  AJNR Am J Neuroradiol       Date:  1989 May-Jun       Impact factor: 3.825

5.  Embolization of cerebral arteriovenous malformations with bucrylate.

Authors:  G Debrun; F Vinuela; A Fox; C G Drake
Journal:  J Neurosurg       Date:  1982-05       Impact factor: 5.115

6.  Endovascular treatment with isobutyl cyano acrylate in patients with arteriovenous malformation of the brain. Indications, results and complications.

Authors:  J J Merland; D Rüfenacht; A Laurent; L Guimaraens
Journal:  Acta Radiol Suppl       Date:  1986

7.  Treatment of cerebral arteriovenous malformations with a combination of preoperative embolization and surgery.

Authors:  A Pasqualin; R Scienza; F Cioffi; G Barone; A Benati; A Beltramello; R Da Pian
Journal:  Neurosurgery       Date:  1991-09       Impact factor: 4.654

8.  Management of hemorrhagic complications from preoperative embolization of arteriovenous malformations.

Authors:  P D Purdy; H H Batjer; D Samson
Journal:  J Neurosurg       Date:  1991-02       Impact factor: 5.115

9.  The effect of embolization with N-butyl cyanoacrylate prior to surgical resection of cerebral arteriovenous malformations.

Authors:  J J Jafar; A J Davis; A Berenstein; I S Choi; M J Kupersmith
Journal:  J Neurosurg       Date:  1993-01       Impact factor: 5.115

10.  Delayed venous occlusion following embolotherapy of vascular malformations in the brain.

Authors:  G R Duckwiler; J E Dion; F Viñuela; A Reichman
Journal:  AJNR Am J Neuroradiol       Date:  1992 Nov-Dec       Impact factor: 3.825

View more
  4 in total

1.  Embolization of brain arteriovenous malformations with the diluted Onyx technique: initial experience.

Authors:  Haowen Xu; Li Wang; Sheng Guan; Dongdong Li; Tao Quan
Journal:  Neuroradiology       Date:  2019-02-02       Impact factor: 2.804

2.  Predictors of neurological deficit after endovascular treatment of cerebral arteriovenous malformations and functional repercussions in prospective follow-up.

Authors:  Jose Jordan; Juan Carlos Llibre; Frank Vazquez
Journal:  Neuroradiol J       Date:  2014-12-01

3.  Airway management in general anesthesia for endovascular treatment of cerebral arteriovenous malformation: a retrospective observational study.

Authors:  Mehmet Anıl Süzer; Mehmet Özgür Özhan; Ceyda Özhan Çaparlar; Mehmet Burak Eşkin; Bülent Atik
Journal:  Braz J Anesthesiol       Date:  2021-12-25

4.  Venous Rupture Following Transcatheter Arterial Embolization for Inferior Mesenteric Type II Arteriovenous Malformation.

Authors:  Kazuki Hirota; Shuji Kariya; Yutaka Ueno; Miyuki Nakatani; Yasuyuki Ono; Takuji Maruyama; Atsushi Komemushi; Mitsunobu Uda; Shinsuke Nishimura; Noboru Tanigawa
Journal:  Interv Radiol (Higashimatsuyama)       Date:  2022-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.